Grace Therapeutics, Inc. (GRCE) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Higher Rate of Favorable Functional Outcomes at 90 Days Versus Oral Nimodipine | 29.00 percent | FY2026-Q3 |
| Reduction in Clinically Significant Hypotension Incidence Versus Oral Nimodipine | 19.00 percent | FY2026-Q3 |
| Number of Patients Administered GTx-104 | 50.00 | FY2026-Q3 |
| Number of Patients Receiving Oral Nimodipine | 52.00 | FY2026-Q3 |
| Patients With Relative Dose Intensity of 95 Percent or Higher (GTx-104) | 54.00 percent | FY2026-Q3 |
| Patients With Relative Dose Intensity of 95 Percent or Higher (Oral Nimodipine) | 8.00 percent | FY2026-Q3 |
| Clinically Significant Hypotension Incidence (GTx-104) | 28.00 percent | FY2026-Q2 |
| Clinically Significant Hypotension Incidence (Oral Nimodipine) | 35.00 percent | FY2026-Q2 |
Back to GRCE overview · GRCE earnings · GRCE holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.